8064-90-2
8064-90-2
Chemical Structure
Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:19)
- CAS No.: 8064-90-2
- Formula:C24H29N7O6S
- Molecular Weight:543.60
InChIKey: WZRJTRPJURQBRM-UHFFFAOYSA-N
SMILES: O=S(NC1=NOC(C)=C1)(C2=CC=C(C=C2)N)=O.NC3=NC=C(CC4=CC(OC)=C(C(OC)=C4)OC)C(N)=N3
Biological Activity: Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:19), an antibacterial agent, is a Trimethoprim (HY-B0510) and Sulfamethoxazole (HY-B0322) mixture. The ratio of Trimethoprim to Sulfamethoxazole in the combination mixture is 1 : 19[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:19) | 99.83% | Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:19), an antibacterial agent, is a Trimethoprim (HY-B0510) and Sulfamethoxazole (HY-B0322) mixture. The ratio of Trimethoprim to Sulfamethoxazole in the combination mixture is 1 : 19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:5) | 99.96% | Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:5), an antibacterial agent, is a Trimethoprim (HY-B0510) and Sulfamethoxazole (HY-B0322) mixture. The ratio of Trimethoprim to Sulfamethoxazole in the combination mixture is 1 : 5. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vaneprim | Vaneprim is an antibacterial agent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tetroxoprim (Standard) | ≥98% | Tetroxoprim (Standard) is the analytical standard of Tetroxoprim. This product is intended for research and analytical applications. Tetroxoprim is an antimicrobial DHFR inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GW2580 | 99.90% | GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim propanoic acid | Trimethoprim propanoic acid is a hapten. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim sulfate | Trimethoprim sulfate is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim sulfate is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim sulfate has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim sulfate can inhibit infection of Influenza A virus in chick embryo when combinated with zinc. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim hydrochloride | 99.16% | Trimethoprim hydrochloride is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim hydrochloride is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim hydrochloride has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim hydrochloride can inhibit infection of Influenza A virus in chick embryo when combinated with zinc. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim lactate (Standard) | 99.01% | Trimethoprim lactate (Standard) is the analytical standard of Trimethoprim lactate (HY-B0510C). This product is intended for research and analytical applications. Trimethoprim lactate is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim lactate is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim lactate has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim lactate can inhibit infection of Influenza A virus in chick embryo when combinated with zinc. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim (Standard) | 99.98% | Trimethoprim (Standard) is the analytical standard of Trimethoprim. This product is intended for research and analytical applications. Trimethoprim is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim can inhibit infection of Influenza A virus in chick embryo when combinated with zinc. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim-d3 | 98.12% | Trimethoprim-d3is the deuterium labeled Trimethoprim. Trimethoprim is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim has the potential for urinary tract infections, Shigellosis and Pneumocystis pneumonia treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trimethoprim-13C3 | Trimethoprim-13C3 is the deuterium labeled Trimethoprim (HY-B0510). Trimethoprim is a bacteriostatic antibiotic and an orally active dihydrofolate reductase inhibitor. Trimethoprim is active against a wide range of Gram-positive and Gram-negative aerobic bacteria. Trimethoprim has the potential for the research of urinary tract infections, Shigellosis and Pneumocystis pneumonia. Trimethoprim can inhibit infection of Influenza A virus in chick embryo when combinated with zinc. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wormser G P, et al. Co-trimoxazole (Trimethoprim-sulfamethoxazole) an updated review of its antibacterial activity and clinical efficacy[J]. Drugs, 1982, 24(6): 459-518.
- [2]. Suthar AB, et al. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ. 2012;90(2):128C-138C. [Content Brief]
